|
UBR3 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 5.66029999999884E-05 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
1.281610E-03 |
| Normal-vs-Stage2 |
2.006200E-02 |
| Normal-vs-Stage3 |
9.08770000029868E-07 |
| Normal-vs-Stage4 |
1.10429999999884E-06 |
| Stage1-vs-Stage2 |
7.909200E-01 |
| Stage1-vs-Stage3 |
9.421800E-03 |
| Stage1-vs-Stage4 |
6.742200E-03 |
| Stage2-vs-Stage3 |
4.521600E-02 |
| Stage2-vs-Stage4 |
2.079700E-02 |
| Stage3-vs-Stage4 |
4.843400E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
4.42140000000979E-06 |
| Normal-vs-AfricanAmerican |
7.601600E-02 |
| Normal-vs-Asian |
9.219300E-04 |
| Caucasian-vs-AfricanAmerican |
2.381000E-01 |
| Caucasian-vs-Asian |
6.663600E-01 |
| AfricanAmerican-vs-Asian |
4.225400E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
1.976440E-04 |
| Normal-vs-Female |
8.41780000000458E-05 |
| Male-vs-Female |
9.368000E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
6.983400E-03 |
| Normal-vs-Age(41-60Yrs) |
4.00040000000379E-05 |
| Normal-vs-Age(61-80Yrs) |
1.70340999999796E-05 |
| Normal-vs-Age(81-100Yrs) |
7.960100E-04 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
5.298000E-02 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
3.902400E-02 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
4.875800E-02 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
6.792200E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
1.662220E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
1.848780E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
1.540160E-03 |
| Classical-VS-Follicular |
2.661400E-01 |
| Classical-VS-Other |
9.817400E-01 |
| Classical-VS-Normal |
2.999800E-04 |
| Tall-VS-Follicular |
5.366700E-04 |
| Tall-VS-Other |
9.986200E-02 |
| Tall-VS-Normal |
4.06880000025645E-07 |
| Follicular-VS-Other |
7.015400E-01 |
| Follicular-VS-Normal |
1.946290E-02 |
| Other-VS-Normal |
1.057200E-01 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
2.751900E-04 |
| Normal-vs-N1 |
1.8993299999992E-05 |
| N0-vs-N1 |
1.344760E-01 |
|
|
